IFNL2 and lung cancer: Microarray mRNA expression analysis of TUSC2 inducible lung cancer cells treated with erlotinib, illustrated in Supplemental Figure 2A,B, uncovered defects in the response to oxidative stress including downregulation of HSPA6, IFNL2, PPP1R15A (GADD34), and GADD45B.